AIRLINK 80.60 Increased By ▲ 1.19 (1.5%)
BOP 5.26 Decreased By ▼ -0.07 (-1.31%)
CNERGY 4.52 Increased By ▲ 0.14 (3.2%)
DFML 34.50 Increased By ▲ 1.31 (3.95%)
DGKC 78.90 Increased By ▲ 2.03 (2.64%)
FCCL 20.85 Increased By ▲ 0.32 (1.56%)
FFBL 33.78 Increased By ▲ 2.38 (7.58%)
FFL 9.70 Decreased By ▼ -0.15 (-1.52%)
GGL 10.11 Decreased By ▼ -0.14 (-1.37%)
HBL 117.85 Decreased By ▼ -0.08 (-0.07%)
HUBC 137.80 Increased By ▲ 3.70 (2.76%)
HUMNL 7.05 Increased By ▲ 0.05 (0.71%)
KEL 4.59 Decreased By ▼ -0.08 (-1.71%)
KOSM 4.56 Decreased By ▼ -0.18 (-3.8%)
MLCF 37.80 Increased By ▲ 0.36 (0.96%)
OGDC 137.20 Increased By ▲ 0.50 (0.37%)
PAEL 22.80 Decreased By ▼ -0.35 (-1.51%)
PIAA 26.57 Increased By ▲ 0.02 (0.08%)
PIBTL 6.76 Decreased By ▼ -0.24 (-3.43%)
PPL 114.30 Increased By ▲ 0.55 (0.48%)
PRL 27.33 Decreased By ▼ -0.19 (-0.69%)
PTC 14.59 Decreased By ▼ -0.16 (-1.08%)
SEARL 57.00 Decreased By ▼ -0.20 (-0.35%)
SNGP 66.75 Decreased By ▼ -0.75 (-1.11%)
SSGC 11.00 Decreased By ▼ -0.09 (-0.81%)
TELE 9.11 Decreased By ▼ -0.12 (-1.3%)
TPLP 11.46 Decreased By ▼ -0.10 (-0.87%)
TRG 70.23 Decreased By ▼ -1.87 (-2.59%)
UNITY 25.20 Increased By ▲ 0.38 (1.53%)
WTL 1.33 Decreased By ▼ -0.07 (-5%)
BR100 7,629 Increased By 103 (1.37%)
BR30 24,842 Increased By 192.5 (0.78%)
KSE100 72,743 Increased By 771.4 (1.07%)
KSE30 24,034 Increased By 284.8 (1.2%)

AMSTERDAM: Siemens Healthineers  on Monday flagged problems at its diagnostics business and toned down expectations for its Atellica blood and urine testing machines, adding that the head of the division would leave the company.

The German health technology firm is pinning its hopes on the Atellica machine to turn around its In-Vitro diagnostics business which lags market leader Roche, but lengthy installation times at large and complex laboratories have dragged down profit in the division.

"We are facing challenges in the diagnostics business," Chief Executive Bernd Montag said.

"We are tackling these issues resolutely and are focusing with our outstanding Atellica Solution Platform vigorously on improving growth and earnings strength," Healthineers said.

Montag will take on responsibility for the diagnostics business as current head Michael Reitermann will leave the company at the end of September, it said.

Healthineers said it expects to ship about 1,800 Atellica machines this year, down from a previous estimate of 2,200-2,500, while upgrades to the system have led to higher costs in the third quarter.

The company in May said measures to improve the roll-out of its new blood and urine testing machines were bearing fruit, and shipments went up to 450 machines in the third quarter from 410 in the previous three months.

But while orders from Europe and Asia were on track, the U.S. market lagged expectations, Healthineers said, and profits at the unit were pressured by higher costs.

Overall, strong sales of medical imaging equipment helped Healthineers post better-than-expected quarterly revenue and earnings growth.

Net profit surged 20% to 353 million euros ($392.75 million) in April-June, beating analysts' average expectations of 328 million euros.

The profit margin dropped from 16% to 15.2% but the company maintained its outlook for a 17.5-18.5% profit margin in its 2019 fiscal year, with 4-5% sales growth.

Comparable sales growth was 6% in the third quarter, also beating market expectations.

Copyright Reuters, 2019

Comments

Comments are closed.